A carregar...
Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial
BACKGROUND: Patients with metastatic castration-resistant prostate cancer (mCRPC) and visceral metastases have a worse prognosis than those with nonvisceral metastases. Treatment with the androgen receptor inhibitor enzalutamide in the phase 3 AFFIRM trial led to significant improvements in outcomes...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5632943/ https://ncbi.nlm.nih.gov/pubmed/27648814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30336 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|